Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Events

Stock Quote

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2019 Results
Call scheduled for today, May 9, at 4:30pm ET TUCSON, Ariz. , May 09, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2019
Toggle Summary HTG Molecular Diagnostics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9
TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2019 after the market close on
Toggle Summary HTG Molecular Expands Agreement with Illumina to Include Autoimmune, Cardiovascular, and Fibrosis Disorders and Diseases
Amendment allows for the development of IVD test kits compatible with Illumina technology TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its
Toggle Summary HTG Introduces the HTG EdgeSeq Mouse mRNA Tumor Response Panel
TUCSON, Ariz. , March 27, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has released a new HTG EdgeSeq Mouse mRNA Tumor Response Panel available now in the United States and
Toggle Summary HTG Molecular Diagnostics Reports Full Year 2018 Results
Revenue increased 46% in 2018 compared to the prior year reflecting continued success growing the company’s profiling business with Pharma company customers TUCSON, Ariz. , March 07, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a life science company whose mission

Stock Chart

SEC Filings

Filing date Description

Securities offered to employees pursuant to employee benefit plans

Report of unscheduled material events or corporate event

Quarterly report which provides a continuing view of a company's financial position

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event